Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that could radically change how certain diseases are treated. The precision and rapid-acting fashion of tools such as zinc-finger nucleases, transcription activator-like effector nucleases, and clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) create untapped opportunity. But gene editing does not come without challenges and controversy, especially when it comes to safety and ethical issues.

This Datamonitor Healthcare report contains a Strategy module.